LGALS3 and neoplasm: As galectin-3 can also act on tumor-infiltrating T cells to impair their anti-tumor function [41], it is possible that these chemically-modified heparin derivatives could possess additional anti-tumor effects in cancer patients as a result of inhibition of galectin-3-mediated T cell apoptosis.